1-3 of 3
Gregory Vosganian
Close
Sort by
Journal Articles

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, Mark Brunvand, MD, Michael Y. Choi, MD, Martin J.S. Dyer, Prof., John Gribben, MDDSc, Peter Hillmen, MB, ChB, PhD, Jeffrey Jones, MD MPH, Yan Li, Mehrdad Mobasher, Gregory Vosganian, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2015) 126 (23): 494.
https://doi.org/10.1182/blood.V126.23.494.494
Published: 2015
Journal Articles

Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Ian Flinn, Mark Brunvand, MD, Martin JS Dyer, Peter Hillman, Jeffrey Jones, James Lymp, PhD, Mostafa Elhamy, BSc,BA, Gregory Vosganian, Jane Huang, Thomas J. Kipps, MD PD
Journal: Blood
Blood (2014) 124 (21): 4687.
https://doi.org/10.1182/blood.V124.21.4687.4687
Published: 2014
Journal Articles

Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Gilles Andre Salles, Thomas E Boyd, MD, Franck Morschhauser, MD PhD, Clemens-Martin Wendtner, MD, James Lymp, PhD, James Hilger, Gregory Vosganian, Jane Huang, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2014) 124 (21): 3337.
https://doi.org/10.1182/blood.V124.21.3337.3337
Published: 2014